Who are Pamiparib capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fuzuloparib , Abiraterone acetate and Prednisone, Fluzoparib; Apatinib, Fluzoparib Capsules, Fluzoparib Monotherapy, Placebo matching Niraparib, Durvalumab + Olaparib phase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pamiparib-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Pamiparib capsule — Competitive Intelligence Brief

Pamiparib capsule (Pamiparib capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PARP inhibitor. Area: Oncology.

phase 3 PARP inhibitor PARP1/PARP2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pamiparib capsule (Pamiparib capsule) — BeiGene. Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pamiparib capsule TARGET	Pamiparib capsule	BeiGene	phase 3	PARP inhibitor	PARP1/PARP2
Fuzuloparib , Abiraterone acetate and Prednisone	Fuzuloparib , Abiraterone acetate and Prednisone	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone)	PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
Fluzoparib; Apatinib	Fluzoparib; Apatinib	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PARP inhibitor + tyrosine kinase inhibitor (combination therapy)	PARP1/PARP2; VEGFR2
Fluzoparib Capsules	Fluzoparib Capsules	The First Affiliated Hospital of Xiamen University	phase 3	PARP inhibitor	PARP1/PARP2
Fluzoparib Monotherapy	Fluzoparib Monotherapy	Tianjin Medical University Cancer Institute and Hospital	phase 3	PARP inhibitor	PARP1/PARP2
Placebo matching Niraparib	Placebo matching Niraparib	Tesaro, Inc.	phase 3	PARP inhibitor (reference: niraparib)	PARP1/PARP2 (reference target)
Durvalumab + Olaparib phase	Durvalumab + Olaparib phase	AstraZeneca	phase 3	PD-L1 inhibitor + PARP inhibitor combination	PD-L1 and PARP1/PARP2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PARP inhibitor class)

AstraZeneca · 5 drugs in this class
BeiGene · 2 drugs in this class
Clovis Oncology, Inc. · 1 drug in this class
Fondazione Ricerca Traslazionale · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sanofi · 1 drug in this class
Tesaro, Inc. · 1 drug in this class
The First Affiliated Hospital of Xiamen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pamiparib capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/pamiparib-capsule. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab